ABSTRACT Background. The susceptibility of patients with rheumatic diseases, and the risks or benefits of immunosuppressive therapies for COVID-19 are unknown. Methods. We performed a retrospective study with patients under follow-up in rheumatology departments from seven hospitals in Spain. We matched updated databases of rheumatology patients with SARS-CoV-2 positive PCR tests performed in the hospital to the same reference populations. Rates of PCR+ confirmed COVID-19 were compared among groups. Results. Patients with chronic inflammatory diseases had 1.32-fold higher prevalence of hospital PCR+ COVID-19 than the reference population (0.76% vs 0.58%). Systemic autoimmune or immune mediated diseases (AI/IMID) patients showed a significant increase, whereas inflammatory arthritis (IA) or systemic lupus erythematosus (SLE) patients did not. COVID-19 cases in some but not all diagnostic groups had older ages than cases in the reference population. IA patients on targeted-synthetic or biological disease-modifying antirheumatic drugs (ts/bDMARD), but not those on conventional-synthetic (csDMARD), had a greater prevalence despite a similar age distribution. Conclusion. Patients with AI/IMID show a variable risk of hospital diagnosed COVID-19. Interplay of aging, therapies, and disease specific factors seem to contribute. These data provide a basis to improve preventive recommendations to rheumatic patients and to analyze the specific factors involved in COVID-19 susceptibility.

中文翻译：

---

慢性炎症和自身免疫性风湿病患者经医院PCR确诊的Covid-19病例的患病率

摘要背景。风湿病患者的易感性以及针对COVID-19的免疫抑制疗法的风险或益处尚不清楚。方法。我们对西班牙七家医院风湿病科的患者进行了回顾性研究。我们将在医院进行的SARS-CoV-2阳性PCR测试的风湿病患者的更新数据库与相同参考人群进行了匹配。比较各组的PCR +确诊COVID-19比率。结果。慢性炎性疾病患者的医院PCR + COVID-19患病率是参考人群的1.32倍（0.76％对0.58％）。全身性自身免疫或免疫介导的疾病（AI / IMID）患者表现出明显的增加，而炎性关节炎（IA）或全身性红斑狼疮（SLE）患者则没有。在某些但并非所有诊断组中，COVID-19病例的年龄均比参考人群的年龄大。尽管年龄分布相似，但接受靶向合成或生物疾病治疗抗风湿药（ts / bDMARD）的IA患者，但未接受常规合成（csDMARD）的IA患者患病率更高。结论。AI / IMID患者显示出医院诊断出COVID-19的可变风险。衰老，疗法和疾病特定因素之间的相互作用似乎有所贡献。这些数据为改善对风湿病患者的预防性建议以及分析COVID-19易感性的具体因素提供了基础。尽管年龄分布相似，但常规合成（csDMARD）的患病率却更高。结论。AI / IMID患者显示出医院诊断出COVID-19的可变风险。衰老，疗法和疾病特定因素之间的相互作用似乎有所贡献。这些数据为改善对风湿病患者的预防性建议以及分析COVID-19易感性的具体因素提供了基础。尽管年龄分布相似，但常规合成（csDMARD）的患病率却更高。结论。AI / IMID患者显示出医院诊断出COVID-19的可变风险。衰老，疗法和疾病特定因素之间的相互作用似乎有所贡献。这些数据为改善对风湿病患者的预防性建议和分析COVID-19易感性的具体因素提供了基础。